XF-73

XF-73
Identifiers
CAS number 718638-68-7 Y
Jmol-3D images Image 1
Properties
Molecular formula C44H50Cl2N6O2
Molar mass 765.81 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

XF-73 is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]

It has completed a phase I clinical trial for nasal decolonisation of MRSA - being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][5]

Structurally it is a dicationic porphyrin.[6]

References